Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.46 |
| ▸ | ITGAL | P20701 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3510050 | 1.00 | ECE1 (0.50) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL30052291 | 0.83 | ECE1 (0.50) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL7184807 | 0.83 | ECE1 (0.50) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL16401 | 0.83 | ECE1 (0.50) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL29203958 | 0.83 | CA2 (0.60) | CA2CA1CA4MME | |
| SCHEMBL29238597 | 0.83 | CA2 (0.60) | CA2CA1CA4MME | |
| SCHEMBL28895692 | 0.83 | CA2 (0.60) | CA2CA1CA4MME | |
| SCHEMBL3049100 | 0.82 | MEN1 (0.49) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL4182303 | 0.82 | ECE1 (0.53) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL4182306 | 0.82 | ECE1 (0.53) | ECE1MEN1KMT2AITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222546-A1 | METHODS FOR THE PREPARATION OF FUNCTIONALIZED PEPTIDES, PROTEINS AND CARBOHYDRATES AND THEIR CONJUGATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-09-02 | — | — | US | disclosed |
| US-7531181-B2 | Gp120 specific antigens and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-05-12 | — | — | US | disclosed |
| WO-2008066816-A2 | DERIVATIZATION OR LIGATON OF PEPTIDES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20070237785-A1 | MULTIPLE ANTIGEN GLYCOPEPTIDE CARBOHYDRATE, VACCINE COMPRISING THE SAME AND USE THEREOF | INSTITUT PASTEUR (FR) | 2007-10-11 | — | — | US | disclosed |
| US-20060229432-A1 | Gp120 specific antigens and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2006-10-12 | — | — | US | disclosed |
| US-20040058859-A1 | Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof | INSTITUT PASTEUR | 2004-03-25 | — | — | US | disclosed |
| US-6676946-B2 | DENDRIMERIC POLYLYSINE HAVING BONDED EPITOPES; CANCER IMMUNO-THERAPY | INSTITUT PASTEUR (FR) | 2004-01-13 | — | — | US | disclosed |
| US-20030157115-A1 | MULTIPLE ANTIGEN GLYCOPEPTIDE CARBOHYDRATE VACCINE COMPRISING THE SAME AND USE THEREOF | INSTITUTE PASTEUR (FR) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058859-A1 | Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof | CD4, SIGLEC7, CD2 | ECE1 2971/4885MEN1 2005/4885KMT2A 602/4885 |
| US-20030157115-A1 | MULTIPLE ANTIGEN GLYCOPEPTIDE CARBOHYDRATE VACCINE COMPRISING THE SAME AND USE THEREOF | CD4, SIGLEC7, CD2 | ECE1 2886/4885MEN1 1978/4885KMT2A 544/4885 |
| US-20070237785-A1 | MULTIPLE ANTIGEN GLYCOPEPTIDE CARBOHYDRATE, VACCINE COMPRISING THE SAME AND USE THEREOF | KLK3, SIGLEC7, LGALS3BP | ECE1 2861/4885MEN1 803/4885KMT2A 963/4885 |
| US-20100222546-A1 | METHODS FOR THE PREPARATION OF FUNCTIONALIZED PEPTIDES, PROTEINS AND CARBOHYDRATES AND THEIR CONJUGATES | PTMS, STT3A, GCG | ECE1 1699/4885MEN1 1820/4885KMT2A 3803/4885 |
| US-20060229432-A1 | Gp120 specific antigens and uses thereof | CD4, CD14, FCGRT | ECE1 1023/4885MEN1 4317/4885KMT2A 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.